EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Real-World Effectiveness and Response Trajectories of Dupilumab in Paediatric Atopic Dermatitis

Małgorzata Ponikowska, Emilia Kucharczyk iD, Karol Biliński iD, Danuta Nowicka iD, Łukasz Lewandowski iD

Journal of Clinical Medicine · 23.06.2026 · 15 (13) · 4862

DOI: 10.3390/jcm15134862 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.06.2026. Verfasst von Małgorzata Ponikowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wroclaw Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Long-term real-world data on dupilumab effectiveness and response trajectories in paediatric atopic dermatitis (AD) remain limited. This study evaluated long-term effectiveness, safety, response durability, and treatment trajectories in paediatric patients with moderate-to-severe AD treated with dupilumab.

Methods

This retrospective single-centre cohort study included 55 paediatric patients with moderate-to-severe AD treated with dupilumab. Clinical outcomes, including Eczema Area and Severity Index (EASI), body surface area (BSA), and Children’s Dermatology Life Quality Index (CDLQI), were assessed longitudinally throughout treatment. The primary endpoint was the achievement of EASI-75 over the course of treatment, including timing of response onset. Secondary endpoints included EASI-90 achievement, longitudinal changes in disease severity and quality of life, treatment durability, safety, and response trajectory analyses. Patients were additionally classified into mutually exclusive trajectory groups based on timing and durability of EASI-75 achievement.

Results

Dupilumab treatment was associated with rapid and sustained clinical improvement. Some patients achieved EASI-75 as early as week 4, highlighting interindividual variability in response kinetics. At week 16, EASI-75 was achieved in 85.5% of patients and EASI-90 in 47.3%. Clinical effectiveness further improved during long-term follow-up, with EASI-75 achieved in 96.2% and EASI-90 in 86.5% of patients at the last available follow-up. Median CDLQI decreased from 22.0 at baseline to 3.0 during follow-up, indicating marked improvement in quality of life. Most patients (83.6%) were classified as early responders, while 10.9% demonstrated delayed but clinically meaningful improvement during continued treatment. Loss of response after initial EASI-75 achievement was uncommon (3.7%). Adverse events were predominantly mild, with eosinophilia and conjunctivitis representing the most frequently observed findings.

Conclusions

Overall, dupilumab demonstrated high long-term effectiveness and favourable tolerability in paediatric patients with moderate-to-severe AD. Trajectory analyses revealed clinically meaningful heterogeneity in response kinetics despite favourable long-term outcomes, highlighting that delayed responders may still achieve substantial benefit during continued therapy.

Schlagwörter

Stichwörter der Autor:innen

EASIatopic dermatitisbiomarkersdupilumabreal-world evidence

Autor:innen und Institutionen

  • Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland.
  • University Centre of General and Oncological Dermatology, University Clinical Hospital in Wroclaw, Borowska 213, 50-556 Wroclaw, Poland.
  • Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.
  • Department of Biochemistry and Immunochemistry, Faculty of Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland.

ORCID-Profile: Emilia Kucharczyk, Karol Biliński, Danuta Nowicka, Łukasz Lewandowski

Förderung

  • Wroclaw Medical University

Zitieren

APA

Ponikowska, M., Kucharczyk, E., Biliński, K., Nowicka, D., & Lewandowski, Ł. (2026). Long-Term Real-World Effectiveness and Response Trajectories of Dupilumab in Paediatric Atopic Dermatitis. Journal of Clinical Medicine, 15(13), 4862. https://doi.org/10.3390/jcm15134862

Vancouver

Ponikowska M, Kucharczyk E, Biliński K, Nowicka D, Lewandowski Ł. Long-Term Real-World Effectiveness and Response Trajectories of Dupilumab in Paediatric Atopic Dermatitis. Journal of Clinical Medicine. 2026;15(13):4862. doi:10.3390/jcm15134862

BibTeX
@article{Ponikowska2026,
  author = {Ponikowska, Małgorzata and Kucharczyk, Emilia and Biliński, Karol and Nowicka, Danuta and Lewandowski, Łukasz},
  title = {Long-Term Real-World Effectiveness and Response Trajectories of Dupilumab in Paediatric Atopic Dermatitis},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {4862},
  doi = {10.3390/jcm15134862}
}
Kostenlos starten →